Johnson & Johnson launches faster PFA system in Europe
Johnson & Johnson has launched its new Varipulse Pro pulsed field ablation (PFA) system in Europe after receiving CE mark approval. This new system is designed to significantly reduce procedure times, being five times faster than its predecessor while maintaining precision. The Varipulse Pro will be showcased at the upcoming European Heart Rhythm Association (EHRA) meeting, where interim results from the VARIPURE study will also be presented.
Global Lung Cancer Surgery Market | Rise at 5.9% CAGR | Medtronic, Ethicon, Intuitive Surgical Drive Precision Oncology Advancements
The global lung cancer surgery market is projected to grow from USD 1.6 billion in 2026 to USD 2.8 billion by 2036, exhibiting a CAGR of 5.9%. This growth is driven by increasing cancer incidence, adoption of minimally invasive and robotic-assisted surgical technologies, and advancements in precision oncology. Key players like Medtronic, Ethicon, and Intuitive Surgical are leading innovation in this evolving market, with segmentectomy being the leading application and hospitals dominating as end-users.
Global Lung Cancer Surgery Market | Rise at 5.9% CAGR | Medtronic, Ethicon, Intuitive Surgical Drive Precision Oncology Advancements
The global lung cancer surgery market is projected to reach USD 2.8 billion by 2036, growing at a CAGR of 5.9% from its 2026 valuation of USD 1.6 billion. This growth is driven by increasing cancer incidence and the adoption of minimally invasive and robotic-assisted surgical technologies. Key players like Medtronic, Ethicon, and Intuitive Surgical are driving advancements in precision oncology, with segmentectomy and hospitals leading the application and end-user segments, respectively.
Blackstone and TPG Complete Acquisition of Hologic
Blackstone and TPG have finalized their acquisition of Hologic, a global leader in women’s health, for up to $79 per share, taking the company private. Joe Almeida has been appointed as the new Chief Executive Officer, effective immediately. The transaction, which includes significant minority investments from ADIA and GIC, aims to accelerate Hologic's innovation and growth in medical technologies.
Johnson & Johnson brings next-gen Varipulse PFA catheter to Europe
Johnson & Johnson has launched its Varipulse Pro system in Europe following CE mark approval. This next-generation pulsed field ablation (PFA) catheter features a new pulse sequence designed to improve procedural efficiency and reinforce safety and effectiveness. The technology offers a lower temperature profile and faster ablation while maintaining integration with the Carto 3 mapping system for precise lesion delivery.
Canaccord cuts Merit Medical stock price target on acquisition impact
Canaccord has lowered its price target for Merit Medical Systems (NASDAQ:MMSI) to $90 from $99, while maintaining a Buy rating, due to the impact of a recent $140 million acquisition. Despite the price target cut and an expected short-term EPS dilution, the acquisition is projected to contribute significantly to revenue and become accretive to non-GAAP EPS by 2027. This news comes amidst mixed analyst views, with BTIG reiterating a Buy rating, but Wells Fargo downgrading the stock to Equal Weight due to concerns over future guidance.
Smart Insulin Management Devices Market is expected to Hit US$ 27.07 Billion by 2033 | Major Companies - Abbott, Medtronic, Tandem Diabetes Care, Inc., Eli Lilly and Company
The Smart Insulin Management Devices Market reached US$ 12.93 Billion in 2024 and is projected to grow to US$ 27.07 Billion by 2033, exhibiting an 8.6% CAGR during the forecast period. This growth is driven by advanced medical devices integrating insulin delivery with real-time monitoring and data analytics to optimize diabetes care. Key players include Abbott, Medtronic, and Eli Lilly, with significant industry developments in cloud-based AI analytics, bundled reimbursement programs, and closed-loop automated insulin delivery systems.
Rathbones Group PLC Sells 12,766 Shares of Medtronic PLC $MDT
Rathbones Group PLC reduced its stake in Medtronic PLC by 19.5% in the fourth quarter, selling 12,766 shares but still holding 52,746 shares valued at approximately $5.07 million. This comes as Medtronic modestly exceeded Q4 expectations and provided optimistic FY2026 guidance, despite a significant insider share sale by EVP Harry Skip Kiil. The company's stock has an average "Moderate Buy" rating from analysts, with a consensus price target of $109.85.
Diabetes device recall surge reveals a worrying information gap
The article highlights a significant increase in diabetes device recalls, particularly for continuous glucose monitors (CGM) and insulin pumps, indicating a growing problem in the medical device industry. This surge in recalls suggests a concerning information gap related to the safety and efficacy of these essential medical devices. The report mentions specific Class I and Class II recalls in 2025 involving major companies like Abbott Laboratories, Tandem Diabetes Care, Dexcom, Medtronic, and Insulet Corp.
Rep. Kevin Hern Sells Comcast Corporation (NASDAQ:CMCSA) Stock
Representative Kevin Hern recently sold between $15,001 and $50,000 worth of Comcast (CMCSA) stock on March 17th, from his HERN FAMILY REVOCABLE TRUST. This transaction was part of several stock sales made by Rep. Hern in March, including shares of Exact Sciences, Prologis, and Texas Instruments. Comcast recently declared a quarterly dividend of $0.33, has a market cap of $99.52 billion, and maintains a "Hold" rating with an average analyst price target of $34.71.
Invesco (NYSE:IVZ) Stock Unloaded Rep. Kevin Hern
Representative Kevin Hern (Republican-Oklahoma) recently sold between $15,001 and $50,000 worth of Invesco (NYSE:IVZ) stock on March 17th, filed on April 3rd, through his family trust. Invesco shares opened at $22.85, were down 5.3%, and the company previously beat quarterly EPS estimates. The firm pays a $0.21 quarterly dividend and holds an average analyst rating of "Hold" with a target price of $28.25.
Rep. Kevin Hern Sells Prologis, Inc. (NYSE:PLD) Stock
Representative Kevin Hern (Republican-Oklahoma) recently sold between $50,001 and $100,000 worth of Prologis, Inc. (NYSE: PLD) stock on March 20th through his family trust. This transaction was part of several recent stock sales by Rep. Hern, including shares in Exact Sciences, T. Rowe Price Group, and Medtronic. Prologis shares were down approximately 1.1% at $132.29, with the company reporting a QEPS of $1.44, revenue of $2.25 billion, and an increased quarterly dividend of $1.07.
Rep. Kevin Hern Sells Off Shares of Medtronic PLC (NYSE:MDT)
Representative Kevin Hern recently sold between $15,001 and $50,000 worth of Medtronic (MDT) shares through his family trust on March 20th, among other significant sales in companies like Smartstop Self Storage REIT and Texas Instruments. Medtronic, a medical technology company, recently surpassed quarterly earnings and revenue estimates, provides a $0.71 quarterly dividend, and holds a "Moderate Buy" consensus rating from MarketBeat with an average target price of $109.85. This transaction is part of a broader pattern of asset trimming by Hern across various stocks in March.
Rep. Kevin Hern Sells Off Shares of T. Rowe Price Group, Inc. (NASDAQ:TROW)
Representative Kevin Hern (R-OK) sold T. Rowe Price Group (NASDAQ:TROW) stock worth between $15,001 and $50,000 on March 20, 2026, through his family trust. The asset manager recently reported Q4 EPS of $2.44, missing estimates, but increased its quarterly dividend to $1.30, providing a 5.8% yield. Analysts currently rate TROW as "Reduce" with an average target price of $100.31, while institutional investors hold approximately 73.4% of the shares.
5 Best 52-Week Low NASDAQ Stocks to Buy Now
This article identifies five NASDAQ stocks that are trading at their 52-week lows and are considered potential buying opportunities. The article features Merit Medical Systems, Inc. (NASDAQ: MMSI) as one of these stocks, detailing its recent acquisition of View Point Medical and a distribution agreement with Medtronic, alongside the commercial release of a new esophageal stent. The full list and methodology are available in an extended version of the article.
Coeur Mining Stock Drops 2.7% Amid Market Volatility
Shares of Coeur Mining Inc. (NYSE:CDE) fell 2.7% on Monday, closing at $18.58, amid broader market declines and volatility in the precious metals mining sector. The drop occurred despite analysts maintaining a 'Moderate Buy' rating and a consensus price target of $24.67, with some firms recently upgrading their outlook or initiating coverage with positive ratings. The company, a significant player in silver and gold production, saw its stock decline along with other mining and materials companies.
Stryker Corporation (SYK) stock price, news, quote and history
This article provides comprehensive financial information for Stryker Corporation (SYK), a medical technology company. It includes real-time stock data, historical performance, key financial metrics, earnings trends, and analyst insights. The company operates globally in medical devices, specializing in MedSurg, Neurotechnology, and Orthopaedics segments.
Boston Scientific Corp. stock: Down 35% but analysts see rebound potential
Despite a 35% drop in Boston Scientific Corp. (BSX) stock over the past six months, major analysts maintain "Buy" ratings, signaling a potential rebound for the medical device company. The stock's decline is attributed to growth concerns, legal issues, and a significant drop after Q4 2025 updates, but the company's strong Q4 performance, innovative portfolio in cardiology and electrophysiology, and high institutional ownership suggest underlying strength. Investors are advised to monitor upcoming Q1 earnings on April 22, 2026, and potential new product launches as key catalysts for recovery.
Sotera Health Shares Are Priced 25% Lower Than Projected Future Cash Flow—Debt Concerns Highlight Increased Safety Margin
The article discusses how recent market volatility creates opportunities for value investors to find undervalued assets with a margin of safety. It highlights Sotera Health as a prime example, trading 25% below its projected future cash flow due to its essential healthcare services and strong competitive moat. However, the company's significant debt burden is noted as a key risk, emphasizing the importance of responsible financial management for long-term growth and compounding returns.
Orchestra BioMed : April 2026 Corporate Presentation
Orchestra BioMed's April 2026 Corporate Presentation highlights its vision to leverage partnerships for innovation and future profitability, focusing on two pivotal trial-stage programs: AVIM Therapy for hypertension and Virtue SAB for artery disease. The company is actively enrolling patients in global pivotal trials for both programs and emphasizes its partnership-driven commercialization strategy for substantial royalty-based revenue. Orchestra BioMed also outlines recent accomplishments, major catalysts expected in 2026-2027, and the significant market opportunities for its cardiovascular treatments.
Boston Scientific closes buyout of Valencia Technologies
Boston Scientific has finalized its acquisition of Valencia Technologies, a move that significantly strengthens its position in the competitive urge urinary incontinence market. The buyout gives Boston Scientific control of eCoin, a tibial nerve stimulator that will compete directly with Medtronic’s Altaviva. Analysts believe this market is largely under-penetrated, offering substantial growth opportunities for Boston Scientific as it leverages its existing urology commercial capabilities.
Stifel Adjusts Price Target on Medtronic to $95 From $105, Maintains Hold Rating
Stifel has lowered its price target for Medtronic (MDT) to $95 from $105, while retaining a Hold rating on the stock. This adjustment comes amidst other analyst revisions for Medtronic on the same day, with Evercore ISI, Argus, and Piper Sandler also updating their price targets. The article also provides a brief company profile of Medtronic, highlighting its diverse medical equipment segments.
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc. (Nasdaq: INGN) has announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective on the date of the company's 2026 Annual Meeting or June 15th if earlier. Jamali, a seasoned medical device executive, is expected to bring significant expertise to Inogen as it transforms into a diversified respiratory care platform. The appointment is part of a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter, who expressed confidence in Inogen's strategic direction.
Medical Foods Market Is Going to Boom |• Abbott • Danone
Worldwide Market Reports has released a comprehensive research study on the Medical Foods Market, forecasting significant growth between 2026 and 2033. The report analyzes key market drivers, challenges, opportunities, and restraints, providing insights into the competitive landscape, market segmentation, and regional trends. It aims to assist stakeholders in making informed investment decisions and understanding the future trajectory of the global Medical Foods market.
Argus Adjusts Price Target on Medtronic to $115 From $125, Maintains Buy Rating
Argus has adjusted its price target for Medtronic (MDT) to $115, down from $125, while maintaining a Buy rating on the stock. This update reflects a re-evaluation by Argus, providing investors with a revised outlook on the medical equipment giant. The article also provides a company profile, recent news, and analyst consensus for Medtronic.
Orthopaedics Market Set to Boom Rapidly by 2033 | Smith & Nephew • DePuy Synthes • NuVasive
Coherent Market Insights has released a comprehensive report titled "Orthopaedics Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033," predicting rapid growth in the orthopaedics sector. The report analyzes market competition, geographic distribution, and growth potential, covering industry performance, success factors, and economic analysis. It serves as a vital tool for entrepreneurs, investors, and business strategists, highlighting major market players like Johnson & Johnson, Stryker Corporation, and Zimmer Biomet.
Savvy Advisors Inc. Buys 6,646 Shares of AbbVie Inc. $ABBV
Savvy Advisors Inc. increased its stake in AbbVie Inc. by 22.2% during the fourth quarter, purchasing 6,646 additional shares to bring its total holdings to 36,568 shares valued at approximately $8.355 million. Meanwhile, several AbbVie executives, including SVP David Ryan Purdue and EVP Perry C. Siatis, sold significant portions of their shares. Analysts maintain a "Moderate Buy" rating for AbbVie, with a consensus target price of $253.15, following the company's strong Q4 earnings beat and optimistic FY2026 guidance.
Perpetual Ltd Sells 97,299 Shares of Medtronic PLC $MDT
Perpetual Ltd significantly reduced its stake in Medtronic PLC, selling 97,299 shares, representing an 88% cut in its holdings. Concurrently, Medtronic EVP Harry Skip Kiil also sold a substantial number of his shares. Despite these sales, Medtronic continues to distribute a quarterly dividend and received a consensus "Moderate Buy" rating from analysts with an average price target of $109.85.
ATRC Should I Buy
Intellectia AI recommends holding AtriCure Inc (ATRC) rather than buying, especially for beginner, long-term investors, due to declining net income and EPS despite revenue growth, coupled with significant competition. Technical indicators show mixed signals, and while some analysts maintain "Buy" ratings, others have downgraded the stock due to competitive risks.
SteelPeak Wealth LLC Invests $3.70 Million in Medtronic PLC $MDT
SteelPeak Wealth LLC recently acquired a new stake of 38,277 shares in Medtronic PLC, valued at approximately $3.70 million. This comes as multiple research firms have initiated or upgraded coverage on Medtronic, leading to a "Moderate Buy" consensus rating and a target price of $109.85. The company also announced a quarterly dividend and favorable quarterly earnings results where it exceeded revenue and EPS expectations.
JPMorgan Chase Boosts Stake in Beta Bionics
JPMorgan Chase has significantly increased its investment in Beta Bionics, a medical device company developing automated insulin delivery solutions for type 1 diabetes. This substantial boost in stake, over 3,200%, indicates growing confidence from Wall Street in Beta Bionics' potential to revolutionize diabetes care with its bionic pancreas technology. The investment firm now holds approximately 0.47% ownership in the Boston-based company.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is transitioning to a critical infrastructure layer in healthcare, valued at USD 4.5 billion in 2026 and projected to reach USD 8.8 billion by 2036 with a CAGR of 6.9%. Growth is driven by standardization, infection control, and the expansion of integrated kits, with North America dominating and India emerging as the fastest-growing market. Key players like Becton, Dickinson and Company, Cardinal Health, Medtronic, Teleflex, and Getinge compete on portfolio coverage and supply continuity.
Medtronic Outperforms MacroGenics in Financial Comparison
A financial analysis comparing Medtronic (NYSE: MDT) and MacroGenics (NASDAQ: MGNX) indicates Medtronic is the stronger investment. Medtronic outperforms MacroGenics in revenue, earnings, profitability, institutional ownership, and analyst recommendations. Its diversified portfolio and financial stability make it a more favorable option than MacroGenics, which carries higher risk due to reliance on a single approved drug.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is projected to grow from USD 4.5 billion in 2026 to USD 8.8 billion by 2036, at a CAGR of 6.9%. This growth is driven by the increasing need for protocol standardization and infection control in surgical and post-acute care, with reliability and seal integrity being key factors for procurement. North America, alongside emerging markets like India and Brazil, is a significant driver of this expansion, while key players such as Becton, Dickinson and Company, and Cardinal Health continue to dominate.
Axonics Inc stock: Why this medtech innovator is worth watching now
Axonics Inc is presented as a compelling investment in the medtech sector, specifically for its innovative sacral neuromodulation system treating bladder and bowel disorders. The article highlights the company's competitive edge through advanced technology, patient-centric design, and a growing market presence in North America. It emphasizes Axonics' strong financial health, consistent revenue growth, and favorable analyst perspectives, while also outlining potential risks for investors to monitor.
Axonics Inc stock: Why this medtech innovator is worth watching now
Axonics Inc is a medical technology company specializing in devices for sacral neuromodulation to treat overactive bladder and bowel disorders. The article highlights Axonics' innovative, long-lasting, and MRI-compatible products as key differentiators in a competitive market, driven by an aging population and increasing demand for effective solutions in North America. Investors should monitor financial health, growth trajectory, and analyst perspectives, while being aware of potential risks such as scaling challenges and reimbursement policy changes.
Stryker Corporation (SYK) stock price, news, quote and history
This page provides a comprehensive overview of Stryker Corporation (SYK), a medical technology company. It includes current stock performance, historical data, financial metrics, and analyst insights. The company operates in MedSurg & Neurotechnology and Orthopaedics segments, offering a wide range of medical devices.
SI-BONE Inc stock: Why this medtech innovator could reshape spine surgery
SI-BONE Inc. is highlighted as a medical technology innovator focusing on sacroiliac (SI) joint dysfunction, an often-overlooked cause of chronic low back pain. The company's minimally invasive iFuse system for SI joint fusion offers a unique solution in the orthopedic market, positioning it as a leader in an underserved niche. Investors are urged to consider SI-BONE for its growth potential, strong market opportunity, and robust financial health, despite typical medtech investment risks.
Genesis Financial Group LLC Acquires Shares of 48,805 Medtronic PLC $MDT
Genesis Financial Group LLC has acquired a new stake of 48,805 shares of Medtronic PLC (NYSE:MDT) during the fourth quarter, valued at approximately $4.69 million, making it the fund's 10th-largest holding. Medtronic recently reported strong quarterly results with EPS of $1.36 and revenue of $9.02 billion, and has provided FY2026 guidance and declared a quarterly dividend. The company's stock shows institutional ownership of over 82%, and analysts have a "Moderate Buy" consensus rating.
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders
Abbott Laboratories recently integrated its Precision Oncology portfolio into Flatiron’s OncoEMR platform, allowing for digital ordering and result delivery of key oncology tests in over 1,600 U.S. community cancer centers. This integration is expected to enhance test utilization and streamline clinical workflows for Abbott (ABT), reinforcing its diagnostics segment. Despite potential benefits from this and other integrations like the Libre CGM data with Epic, the company still faces challenges such as margin pressure from tariffs and pricing in China and competitive pressures in diagnostics and diabetes care.
Catheter Precision seeks buyer for cardiac device business By Investing.com
Catheter Precision Inc. is seeking a buyer for its cardiac electrophysiology business, which includes FDA and CE Mark approved products LockeT and VIVO, to focus on its Flyte aviation platform. Despite the cardiac business having a high gross profit margin of 92.31%, the company's market capitalization is low, and its stock has significantly declined. Catheter Precision believes monetizing these assets will unlock value and allow it to be valued as a pure-play aviation business.
Intuitive Surgical, Inc. Stock: Leader in Robotic-Assisted Surgery Faces Growth Challenges Amid Mark
Intuitive Surgical, Inc. (ISRG) dominates the robotic-assisted surgery market with its da Vinci systems, known for precision and reduced patient recovery times. Despite its strong market position and robust procedure growth, the company faces challenges from increasing competition from companies like Medtronic and Johnson & Johnson, as well as risks associated with regulatory scrutiny and potential economic headwinds impacting elective surgeries. Investors are drawn to ISRG for its innovative technology and growth potential, but are advised to monitor competitive developments and the adoption rates of new platforms.
Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North America Leads with 42% Share - Key Players: Becton, Dickinson and Company, Hologic Inc., Boston Scientific Corporation
The global biopsy devices market is projected to reach US$ 6.85 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.15% from US$ 2.68 billion in 2025. This growth is primarily driven by the increasing prevalence of cancer and other chronic diseases, alongside advancements in minimally invasive and image-guided biopsy technologies. North America is expected to maintain its leading position in the market, holding a 42% share, due to its advanced healthcare infrastructure and early adoption of innovative diagnostic tools.
Medtronic PLC $MDT Stake Increased by HF Advisory Group LLC
HF Advisory Group LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 290.2% in Q4, acquiring 44,212 additional shares to hold a total of 59,447 shares valued at $5.71 million. This increase comes as Medtronic exceeded Q4 earnings and revenue estimates and announced a quarterly dividend of $0.71 per share. Despite an insider sale by EVP Harry Skip Kiil, institutional investors collectively own 82.06% of the company's stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $109.85.
DiNuzzo Private Wealth Inc. Reduces Stock Position in Dimensional Emerging Markets Core Equity 2 ETF $DFEM
DiNuzzo Private Wealth Inc. reduced its stake in the Dimensional Emerging Markets Core Equity 2 ETF (DFEM) by 4.1% in the fourth quarter, selling 31,833 shares to hold 735,429 shares valued at $24.33 million. DFEM represents 2.6% of the firm's portfolio, making it their 13th largest position. Several other institutional investors also adjusted their holdings in DFEM, with entities like Two West Capital Advisors LLC and Silver Oak Securities Incorporated increasing their stakes.
Intuitive Surgical Stock Near Crucial Support – Buy Signal?
Intuitive Surgical (ISRG) stock is currently trading within a crucial support zone, having bounced significantly from these levels multiple times in the past. The article suggests a rebound is likely due to robust sector growth, strong Q4 2025 performance, and a growing robotic surgery market. Despite competitive pressures and an elevated valuation, analyst targets imply significant upside, while technical indicators like an oversold RSI also support a potential bounce.
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
William Blair initiated coverage on MiniMed Group Inc. (NASDAQ: MMED), highlighting its recovery story despite past competitive setbacks. The company, a unit of Medtronic Plc, is improving its product pipeline with new innovations like the MiniMed Flex, a next-generation insulin pump cleared by the FDA. Despite facing ongoing competition and profitability challenges, its valuation presents an attractive risk-reward profile for investors.
A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market
Anteris Technologies (ASX:AVR, NASDAQ:AVR) is aiming to disrupt the $10 billion transcatheter aortic valve replacement (TAVR) market with its DurAVR program. Unlike existing devices from dominant players like Edwards Lifesciences and Medtronic, Anteris's DurAVR valve was designed from scratch to mimic a native valve, offering both ease of use (balloon-expandable delivery) and superior haemodynamic performance. This innovation addresses the growing need for more durable and physiologically sound valves for younger TAVR patients and aims to resolve the long-standing trade-off between ease of use and optimal blood flow in the market.
Medtronic plc Stock: Navigating Transformation and Growth in MedTech Amid Analyst Shifts
Medtronic plc is undergoing a strategic transformation, including the potential spinoff of its diabetes business, following solid Q3 FY2026 results that surpassed analyst estimates. The company, a leader in medical devices, shows resilience and aims for renewed growth by streamlining operations and focusing on high-margin therapies. Despite mixed analyst views and execution risks associated with the spinoff, Medtronic's strong financial performance, reliable dividend, and market position in cardiovascular and surgical technologies make it an attractive option for North American investors seeking defensive growth in the healthcare sector.
Medtronic plc Stock: Navigating Transformation and Growth in MedTech Amid Analyst Shifts
Medtronic plc is undergoing a significant transformation, including a planned spinoff of its MiniMed diabetes business, and reported strong Q3 FY2026 results with revenue of $9.02 billion. The company is focused on high-margin therapies and boasts a robust dividend policy, approaching Dividend King status. While analysts show mixed views, with Barclays raising its target to $120, execution risks related to the spinoff and competitive pressures remain key areas for investors to monitor.
